Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

This trial showed significantly longer progression-free survival and overall survival with first-line treatment with EC+mFOLFOX6 than with standard care among patients with BRAF V600E–mutated metastatic colorectal cancer.